Breaking News, Collaborations & Alliances

Integral Molecular, AstraZeneca Enter Oncology Antibody Alliance

AstraZeneca has an exclusive license to a collection of highly specific monoclonal antibodies for use in oncology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Integral Molecular, a developer of antibodies against membrane proteins, entered an exclusive worldwide antibody license agreement with AstraZeneca to develop therapeutics for multiple cancers.   Integral Molecular will provide an exclusive license to AstraZeneca for a collection of highly specific monoclonal antibodies for use in oncology. AstraZeneca will be responsible for all research, development, and commercial activities.   The antibodies licensed by AstraZeneca were discovered and ch...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters